|

CAR-T Clinical Trials

10 actively recruiting trials across 1 location

Pipeline

Early 1: 1Phase 1: 2Phase 2: 1Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Institute of Hematology & Blood Diseases Hospital, China2
  • Guangzhou Bio-gene Technology Co., Ltd2
  • The Third Affiliated Hospital of Southern Medical University1
  • Peking University People's Hospital1
  • Memorial Sloan Kettering Cancer Center1

Indications

  • Cancer10
  • Multiple Myeloma2
  • MRD-positive1
  • Allogenetic Hematopoietic Stem Cell Transplantation1
  • Gliomas1

Other9 trials

A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
Early 1
CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
N/A
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Phase 1
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
N/A
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Phase 1/2
Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer
N/A
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
Phase 2
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Phase 1

New York, New York1 trial

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.